HOW LONG WILL THe Response Last?

19 months ago I began a journey with a suspicion by CT, observation by cystoscopy and confirmation after transurethral resection of bladder tumor (TURBT) and PET/CT imaging of locally advanced muscle invasive bladder cancer.  16 months ago I began treatment with enfortumab vedotin and pembrolizumab (EV/pembro - Padcev/Keytruda). I currently have  no evidence of disease (NED) by circulating tumor DNA (tumor informed Signatera and tumor naive Response). My next surveillance CT, scheduled for May 13, will determine if this trend continues by  imaging as well.  If I remain NED, my current treatment (pembrolizumab only)  will be suspended this Christmas (two years).
In the EV 302 trial, 29% of participants receiving EV/pembro had a confirmed complete response (cCR).  Dr. Thomas Powles presented an updated analysis from the EV302 trial at the ASCO GU 2025 in February - including data on the duration of cCR by blinded independent central review (BICR) of imaging data.  The performance is sufficiently good that there hasn't been enough time to follow patients  to estimate a median cCR duration.  At 16 months from beginning treatment about 80% of those achieving cCR had maintained it.  The EV302 results look encouraging if I remain NED through Christmas (24 months)... 

Updated EV302 data presented at ASCO GU 2025 - Dr. T. Powles